Duchenne News Tags: Sarepta

June 22, 2023
Sarepta announces U.S. Food and Drug Administration accelerated approval of ELEVIDYS.
June 8, 2023
Sarepta shares enrollment updates for SRP-9001-303 study.
May 24, 2023
Sarepta shares an update on the regulatory review of SRP-9001, a treatment of ambulant individuals with Duchenne muscular dystrophy who have a confirmed mutation of the DMD gene.
April 11, 2023
Sarepta Therapeutics Announces May 12, 2023 as Date of Advisory Committee Meeting for SRP-9001
March 17, 2023
Sarepta announces advisory meeting for SRP-9001, an investigational gene therapy for the treatment of Duchenne muscular dystrophy.
February 28, 2023
Sarepta announces official release of 2023-2024 Route 79 Duchenne Scholarship Program
November 28, 2022
Sarepta announces FDA filing and priority review for biologics license application for SRP-9001
September 29, 2022
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy.
September 13, 2022
On September 13, 2022, Sarepta Therapeutics shared an update announcing that their EMBARK (SRP-9001-301) study is fully enrolled.
September 7, 2022
On Sept. 7, 2022, Sarepta Therapeutics announced the recipients for its Route 79, Duchenne Scholarship Program for the 2022-2023 academic year.
September 6, 2022
On Sept. 6, 2022, Sarepta Therapeutics announced that the Food and Drug Administration lifted its clinical hold on SRP-5051 for the treatment of Duchenne muscular dystrophy.
July 6, 2022
On July 6, 2022, Sarepta Therapeutics shared new functional data across multiple studies from the clinical development program for investigational gene therapy SRP-9001.
June 23, 2022
On June 23, 2022, Sarepta shared news regarding the MOMENTUM study.

Experience the magic of camp promise

Complete applications due April 3, 2023.